Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To evaluate the safety of rituximab maintenance therapy following a rituximab-containing induction regimen in first line or relapsed patients with follicular Non-Hodgkin’s Lymphoma
Critère d'inclusion
- First line or relapsed patients with Grade 1, 2 or 3a, CD20+ follicular non- Hodgkins's Lymphoma who respond to rituximab- containing induction therapy